HER2-low breast cancer. Diagnostics, treatment and its adverse events
Journal of Education, Health and SportIntroduction: Breast cancer is one of the most commonly diagnosed malignant tumors among women worldwide. HER2 receptor is a protein that plays a role in cell growth, division, and repair.
Hanna Bartkowiak +7 more
doaj +1 more source
Trastuzumab deruxtecan for breast cancer: do patients experience a comprehensive benefit? [PDF]
, 2023 Fernanda Mosele, Massimo Di Maïo
openalex +1 more source
Potential Targets and Biomarkers of Radionuclide Therapy in Breast Cancer
Cancer Innovation, Volume 5, Issue 1, February 2026.Potential biomarkers for the development of targeted radionuclide therapy that can be employed in the treatment of breast cancer have been summarised in the review. They include receptor markers of ER, PR and HER2, as well as other markers of Trop2, PD‐1, EGFR, GRPR and PSMA.
Yujing Tan +3 more
wiley +1 more source
A Clinical Guidance for the Management of Patients With Hepatoid Adenocarcinoma and A Case Series
Cancer Medicine, Volume 15, Issue 2, February 2026.ABSTRACT Hepatoid adenocarcinoma (HAC) is a rare extrahepatic tumor of non‐germ cell origin that morphologically resembles hepatocellular carcinoma (HCC). HAC has a propensity to metastasize to the liver and therefore may be mistaken for HCC. There is a lack of standardized treatment protocols, and further studies are needed to evaluate the benefit of ...
Christina Liava +4 more
wiley +1 more source
1321MO Trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2 (ERBB2)-mutant (HER2m) metastatic non–small cell lung cancer (NSCLC) with and without brain metastases (BMs): Pooled analyses from DESTINY-Lung01 and DESTINY-Lung02 [PDF]
, 2023 B.T. Li +19 more
openalex +1 more source
HeliyonAntibody drug conjugates (ADCs) are novel drugs that exert specific cytotoxicity against breast cancer. Although ADCs such as trastuzumab emtansine and trastuzumab deruxtecan have significantly improved survival for patients with breast cancer expressing
Hanghang Ma, Jianbin Li
doaj +1 more source
147P Pharmacokinetics, safety, and efficacy of trastuzumab deruxtecan (T-DXd) with OATP1B/CYP3A inhibitors in patients with HER2-expressing advanced solid tumours [PDF]
, 2020 Masato Takahashi +14 more
openalex +1 more source
Cancer Reports, Volume 9, Issue 2, February 2026.ABSTRACT Background Orbital metastases are rare in patients with breast cancer. However, medical management of orbital metastases is limited by the inability of treatment options to penetrate the blood‐brain barrier. In patients with triple negative breast cancer (TNBC), these treatment options are further limited.
Nellie Nafissi +4 more
wiley +1 more source
Advances of antibody-drug conjugates in the treatment of metastatic triple-negative breast cancer [PDF]
Waike lilun yu shijianTriple-negative breast cancer (TNBC) is insensitive to endocrine therapy or anti-human epidermal growth factor receptor(HER)-2 targeted therapy due to its lack of expression of hormone receptors and HER-2.
TONG Yiwei, CHEN Xiaosong
doaj +1 more source
Anti‐Her2 therapy patterns in metastatic breast cancer—Real‐world data suggest undertreatment
International Journal of Cancer, Volume 158, Issue 3, Page 633-641, 1 February 2026.What's new? Although human epidermal growth factor 2‐positive (HER2+) breast cancer is an aggressive malignancy, significant survival benefits are possible with targeted anti‐HER2 therapies. Whether these therapies are used as recommended, however, is unknown. Here, the authors investigated data from population‐based registries in Norway to assess anti‐
Kathrine F. Vandraas +9 more
wiley +1 more source